Semper Paratus Acquisition Corporation Files Registration Statement on Form S-4 in Connection with Proposed Business Combination with Tevogen Bio Inc

[ad_1] New York, NY, Sept. 14, 2023 (GLOBE NEWSWIRE) — Semper Paratus Acquisition Corporation (Nasdaq: LGST) (“Semper Paratus”), a publicly traded special purpose acquisition company, today announced the filing of…

Tevogen Bio to Become Publicly Listed on NYSE via Business Combination with Semper Paratus Acquisition Corporation

[ad_1] Semper Paratus Acquisition Corporation Tevogen Bio Inc. (“Tevogen Bio”) is an advanced-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology. Founded…